Skip to main content
Erschienen in:

02.12.2019 | Research Paper

A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence

verfasst von: Jingni He, Zhong Tian, Xu Yao, Baiyu Yao, Yuan Liu, Jiapeng Yang

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

The papillary thyroid carcinoma (PTC) usually shows an excellent prognosis. But some patients suffer recurrence after treatment. Recent progress in RNA sequencing (RNA-Seq) allows us to explore whole-transcriptomic gene expression profiles to develop RNA-seq based predictive model for stratifying the risk of recurrence of PTC. RNA-seq and clinical data from The Cancer Genome Atlas thyroid carcinoma cohort were divided chronologically into a training cohort (before 2011, n = 240) and a validation cohort (after 2011, n = 239). A risk score model was developed in training cohort using univariate Cox analysis followed by stepwise multivariate Cox analysis, and assessed in the validation cohort. Univariate and multivariate analyses identified five independent predictive genes (TOP2A, RP11-180M15.7, RP11-635N19.1, PROSER3, and TMEM139) significantly (p < 0.05) associated with recurrence-free survival of PTC. The proposed risk score model defined by these five genes was able to divide patients into high-risk and low-risk groups with significantly different recurrence risk in both training cohort [hazard ratio (HR) 6.62, 95% confidence interval (CI) 3.16–13.86] and validation cohort [HR 3.40, 95% CI1.29–8.94). Furthermore, the model is independent of clinicopathologic factors and demonstrated better predictive performance than other clinical covariates in PTC patients with no distant metastasis. Our results indicate that TOP2A, RP11-180M15.7, RP11-635N19.1, PROSER3, and TMEM139 are potential independent predictive genes for the recurrence of PTC and the proposed RNA sequencing-based model has significant predictive value and may improve recurrence risk stratification for early-stage PTC patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133PubMedPubMedCentralCrossRef Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMed
3.
Zurück zum Zitat Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140(4):317–322PubMedCrossRef Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140(4):317–322PubMedCrossRef
4.
Zurück zum Zitat Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS (2011) Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 21(2):125–134PubMedPubMedCentralCrossRef Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS (2011) Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 21(2):125–134PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A (2018) Overall survival of papillary thyroID carcinoma patients: a single-institution long-term follow-up of 5897 patients. World J Surg 42(3):615–622PubMedPubMedCentralCrossRef Ito Y, Miyauchi A, Kihara M, Fukushima M, Higashiyama T, Miya A (2018) Overall survival of papillary thyroID carcinoma patients: a single-institution long-term follow-up of 5897 patients. World J Surg 42(3):615–622PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338(5):297–306PubMedCrossRef Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338(5):297–306PubMedCrossRef
7.
Zurück zum Zitat Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A (2012) Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg 36(6):1274–1278PubMedCrossRef Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A (2012) Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg 36(6):1274–1278PubMedCrossRef
8.
Zurück zum Zitat Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20(12):1341–1349PubMedPubMedCentralCrossRef Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20(12):1341–1349PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Baek SK, Jung KY, Kang SM, Kwon SY, Woo JS, Cho SH, Chung EJ (2010) Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid 20(2):147–152PubMedCrossRef Baek SK, Jung KY, Kang SM, Kwon SY, Woo JS, Cho SH, Chung EJ (2010) Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid 20(2):147–152PubMedCrossRef
10.
Zurück zum Zitat Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, Vaisman M, Tuttle RM (2012) Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol 77(1):132–138CrossRef Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, Vaisman M, Tuttle RM (2012) Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol 77(1):132–138CrossRef
11.
Zurück zum Zitat Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214PubMedCrossRef Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167–1214PubMedCrossRef
12.
Zurück zum Zitat Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM (2013) Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid 23(11):1401–1407PubMedCrossRef Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM (2013) Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid 23(11):1401–1407PubMedCrossRef
13.
Zurück zum Zitat Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini F (2011) Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 165(3):441–446PubMedCrossRef Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini F (2011) Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 165(3):441–446PubMedCrossRef
14.
Zurück zum Zitat Pathak KA, Mazurat A, Lambert P, Klonisch T, Nason RW (2013) Prognostic nomograms to predict oncological outcome of thyroid cancers. J Clin Endocrinol Metab 98(12):4768–4775PubMedCrossRef Pathak KA, Mazurat A, Lambert P, Klonisch T, Nason RW (2013) Prognostic nomograms to predict oncological outcome of thyroid cancers. J Clin Endocrinol Metab 98(12):4768–4775PubMedCrossRef
15.
Zurück zum Zitat Lang BH-H, Wong CK (2015) Validation and comparison of nomograms in predicting disease-specific survival for papillary thyroid carcinoma. World J Surg 39(8):1951–1958PubMedCrossRef Lang BH-H, Wong CK (2015) Validation and comparison of nomograms in predicting disease-specific survival for papillary thyroid carcinoma. World J Surg 39(8):1951–1958PubMedCrossRef
16.
Zurück zum Zitat Lang BH, Wong CK, Yu HW, Lee KE (2016) Postoperative nomogram for predicting disease-specific death and recurrence in papillary thyroid carcinoma. Head Neck 38(S1):E1256–E1263PubMedCrossRef Lang BH, Wong CK, Yu HW, Lee KE (2016) Postoperative nomogram for predicting disease-specific death and recurrence in papillary thyroid carcinoma. Head Neck 38(S1):E1256–E1263PubMedCrossRef
17.
Zurück zum Zitat Jianyong L, Jinjing Z, Zhihui L, Tao W, Rixiang G, Jingqiang Z (2018) A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence. Thyroid 28(3):301–310PubMedCrossRef Jianyong L, Jinjing Z, Zhihui L, Tao W, Rixiang G, Jingqiang Z (2018) A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence. Thyroid 28(3):301–310PubMedCrossRef
18.
Zurück zum Zitat Xing M (2010) Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321(1):86–93PubMedCrossRef Xing M (2010) Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321(1):86–93PubMedCrossRef
19.
Zurück zum Zitat Vuong HG, Altibi AMA, Duong UNP, Hassell L (2017) Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin Endocrinol 87(5):411–417CrossRef Vuong HG, Altibi AMA, Duong UNP, Hassell L (2017) Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin Endocrinol 87(5):411–417CrossRef
20.
Zurück zum Zitat Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C (2015) Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 33(1):42–50PubMedCrossRef Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C (2015) Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 33(1):42–50PubMedCrossRef
21.
Zurück zum Zitat Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C (2012) The BRAF V600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97(12):4390–4398PubMedCrossRef Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C (2012) The BRAF V600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97(12):4390–4398PubMedCrossRef
22.
Zurück zum Zitat Li C, Lee KC, Schneider EB, Zeiger MA (2012) BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 97(12):4559–4570PubMedPubMedCentralCrossRef Li C, Lee KC, Schneider EB, Zeiger MA (2012) BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 97(12):4559–4570PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C (2014) TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99(5):E754–E765PubMedPubMedCentralCrossRef Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C (2014) TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99(5):E754–E765PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J (2014) BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32(25):2718–2726PubMedPubMedCentralCrossRef Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J (2014) BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32(25):2718–2726PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Tanaka A, Matsuse M, Saenko V, Nakao T, Yamanouchi K, Sakimura C, Yano H, Nishihara E, Hirokawa M, Suzuki K, Miyauchi A, Eguchi S, Yoshiura KI, Yamashita S, Nagayasu T, Mitsutake N (2019) TERT mRNA expression as a novel prognostic marker in papillary thyroid carcinomas. Thyroid 29(8):1105–1114PubMedCrossRef Tanaka A, Matsuse M, Saenko V, Nakao T, Yamanouchi K, Sakimura C, Yano H, Nishihara E, Hirokawa M, Suzuki K, Miyauchi A, Eguchi S, Yoshiura KI, Yamashita S, Nagayasu T, Mitsutake N (2019) TERT mRNA expression as a novel prognostic marker in papillary thyroid carcinomas. Thyroid 29(8):1105–1114PubMedCrossRef
26.
Zurück zum Zitat Vuong HG, Duong UN, Altibi AM, Ngo HT, Pham TQ, Tran HM, Gandolfi G, Hassell L (2017) A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocr Connect 6(3):R8–Rr17PubMedPubMedCentralCrossRef Vuong HG, Duong UN, Altibi AM, Ngo HT, Pham TQ, Tran HM, Gandolfi G, Hassell L (2017) A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocr Connect 6(3):R8–Rr17PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69(11):4885–4893PubMedPubMedCentralCrossRef Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69(11):4885–4893PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Ma B, Liao T, Wen D, Dong C, Zhou L, Yang S, Wang Y, Ji Q (2016) Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer. Sci Rep 6:36973PubMedPubMedCentralCrossRef Ma B, Liao T, Wen D, Dong C, Zhou L, Yang S, Wang Y, Ji Q (2016) Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer. Sci Rep 6:36973PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Sondermann A, Andreghetto FM, Moulatlet ACB, da Silva Victor E, de Castro MG, Nunes FD, Brandão LG, Severino P (2015) MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer. Clin Exp Metastasis 32(6):521–530PubMedCrossRef Sondermann A, Andreghetto FM, Moulatlet ACB, da Silva Victor E, de Castro MG, Nunes FD, Brandão LG, Severino P (2015) MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer. Clin Exp Metastasis 32(6):521–530PubMedCrossRef
30.
Zurück zum Zitat Wang M, Lindberg J, Klevebring D, Nilsson C, Lehmann S, Grönberg H, Rantalainen M (2018) Development and validation of a novel RNA sequencing–based prognostic score for acute myeloid leukemia. J Natl Cancer Inst 110(10):1094–1101PubMedPubMedCentralCrossRef Wang M, Lindberg J, Klevebring D, Nilsson C, Lehmann S, Grönberg H, Rantalainen M (2018) Development and validation of a novel RNA sequencing–based prognostic score for acute myeloid leukemia. J Natl Cancer Inst 110(10):1094–1101PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM (2017) Development of a RNA-Seq based prognostic signature in lung adenocarcinoma. J Natl Cancer Inst 109(1):djw200CrossRef Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM (2017) Development of a RNA-Seq based prognostic signature in lung adenocarcinoma. J Natl Cancer Inst 109(1):djw200CrossRef
32.
Zurück zum Zitat Zhou M, Zhang Z, Zhao H, Bao S, Cheng L, Sun J (2018) An immune-related six-lncRNA signature to improve prognosis prediction of glioblastoma multiforme. Mol Neurobiol 55(5):3684–3697PubMed Zhou M, Zhang Z, Zhao H, Bao S, Cheng L, Sun J (2018) An immune-related six-lncRNA signature to improve prognosis prediction of glioblastoma multiforme. Mol Neurobiol 55(5):3684–3697PubMed
33.
Zurück zum Zitat Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M (2013) Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol 31(9):1172–1181PubMedPubMedCentralCrossRef Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M (2013) Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol 31(9):1172–1181PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat The Cancer Genome Atlas Research Network (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676–690CrossRef The Cancer Genome Atlas Research Network (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676–690CrossRef
35.
Zurück zum Zitat Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I (2015) TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 44(8):e71–e71PubMedPubMedCentralCrossRef Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I (2015) TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 44(8):e71–e71PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S (2012) GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res 22(9):1760–1774PubMedPubMedCentralCrossRef Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S (2012) GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res 22(9):1760–1774PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q (2015) Comprehensive genomic characterization of long non-coding RNAs across human cancers. Cancer Cell 28(4):529–540PubMedPubMedCentralCrossRef Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q (2015) Comprehensive genomic characterization of long non-coding RNAs across human cancers. Cancer Cell 28(4):529–540PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Li J, Tibshirani R (2013) Finding consistent patterns: a nonparametric approach for identifying differential expression in RNA-Seq data. Stat Methods Med Res 22(5):519–536PubMedCrossRef Li J, Tibshirani R (2013) Finding consistent patterns: a nonparametric approach for identifying differential expression in RNA-Seq data. Stat Methods Med Res 22(5):519–536PubMedCrossRef
39.
Zurück zum Zitat Bozdogan H (1987) Model selection and Akaike's information criterion (AIC): The general theory and its analytical extensions. Psychometrika 52(3):345–370CrossRef Bozdogan H (1987) Model selection and Akaike's information criterion (AIC): The general theory and its analytical extensions. Psychometrika 52(3):345–370CrossRef
40.
Zurück zum Zitat Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG (2018) Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst 110(8):803–811PubMedPubMedCentralCrossRef Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG (2018) Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst 110(8):803–811PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Wagenmakers EJ, Farrell S (2004) AIC model selection using Akaike weights. Psychon Bull Rev 11(1):192–196PubMedCrossRef Wagenmakers EJ, Farrell S (2004) AIC model selection using Akaike weights. Psychon Bull Rev 11(1):192–196PubMedCrossRef
42.
Zurück zum Zitat Lee S, Jung S-R, Heo K, Byl JAW, Deweese JE, Osheroff N, Hohng S (2012) DNA cleavage and opening reactions of human topoisomerase IIα are regulated via Mg2+-mediated dynamic bending of gate-DNA. Proc Natl Acad Sci USA 109(8):2925–2930PubMedCrossRefPubMedCentral Lee S, Jung S-R, Heo K, Byl JAW, Deweese JE, Osheroff N, Hohng S (2012) DNA cleavage and opening reactions of human topoisomerase IIα are regulated via Mg2+-mediated dynamic bending of gate-DNA. Proc Natl Acad Sci USA 109(8):2925–2930PubMedCrossRefPubMedCentral
43.
Zurück zum Zitat Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 12(12):1134–1142PubMedCrossRef Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 12(12):1134–1142PubMedCrossRef
44.
Zurück zum Zitat Milde-Langosch K, Karn T, Müller V, Witzel I, Rody A, Schmidt M, Wirtz RM (2013) Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res Treat 137(1):57–67PubMedCrossRef Milde-Langosch K, Karn T, Müller V, Witzel I, Rody A, Schmidt M, Wirtz RM (2013) Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res Treat 137(1):57–67PubMedCrossRef
45.
Zurück zum Zitat Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku S-Y, Sjöström M, Alshalalfa M, Erho N (2017) TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin Cancer Res 23(22):7072–7083PubMedPubMedCentralCrossRef Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku S-Y, Sjöström M, Alshalalfa M, Erho N (2017) TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clin Cancer Res 23(22):7072–7083PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Ito F, Furukawa N, Nakai T (2016) Evaluation of TOP2A as a predictive marker for endometrial cancer with taxane-containing adjuvant chemotherapy. Int J Gynecol Cancer 26(2):325–330PubMedCrossRef Ito F, Furukawa N, Nakai T (2016) Evaluation of TOP2A as a predictive marker for endometrial cancer with taxane-containing adjuvant chemotherapy. Int J Gynecol Cancer 26(2):325–330PubMedCrossRef
47.
Zurück zum Zitat Chen D, Maruschke M, Hakenberg O, Zimmermann W, Stief CG, Buchner A (2017) TOP2A, HELLS, ATAD2, and TET3 are novel prognostic markers in renal cell carcinoma. Urology 102:265. e261-265. e267PubMedCrossRef Chen D, Maruschke M, Hakenberg O, Zimmermann W, Stief CG, Buchner A (2017) TOP2A, HELLS, ATAD2, and TET3 are novel prognostic markers in renal cell carcinoma. Urology 102:265. e261-265. e267PubMedCrossRef
48.
Zurück zum Zitat Pita J, Banito A, Cavaco B, Leite V (2009) Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer 101(10):1782–1791PubMedPubMedCentralCrossRef Pita J, Banito A, Cavaco B, Leite V (2009) Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer 101(10):1782–1791PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE (2006) Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16(2):161–175PubMedCrossRef Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE (2006) Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16(2):161–175PubMedCrossRef
50.
Zurück zum Zitat Zhang R, Hardin H, Chen J, Guo Z, Lloyd RV (2016) Non-coding RNAs in thyroid cancer. Endocr Pathol 27(1):12–20PubMedCrossRef Zhang R, Hardin H, Chen J, Guo Z, Lloyd RV (2016) Non-coding RNAs in thyroid cancer. Endocr Pathol 27(1):12–20PubMedCrossRef
51.
Zurück zum Zitat Pan W, Zhou L, Ge M, Zhang B, Yang X, Xiong X, Fu G, Zhang J, Nie X, Li H (2016) Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations. Hum Mol Gen 25(9):1875–1884PubMedCrossRef Pan W, Zhou L, Ge M, Zhang B, Yang X, Xiong X, Fu G, Zhang J, Nie X, Li H (2016) Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations. Hum Mol Gen 25(9):1875–1884PubMedCrossRef
52.
Zurück zum Zitat Zhang R, Hardin H, Huang W, Buehler D, Lloyd RV (2018) Long non-coding RNA Linc-ROR is upregulated in papillary thyroid carcinoma. Endocr Pathol 29(1):1–8PubMedCrossRef Zhang R, Hardin H, Huang W, Buehler D, Lloyd RV (2018) Long non-coding RNA Linc-ROR is upregulated in papillary thyroid carcinoma. Endocr Pathol 29(1):1–8PubMedCrossRef
Metadaten
Titel
A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence
verfasst von
Jingni He
Zhong Tian
Xu Yao
Baiyu Yao
Yuan Liu
Jiapeng Yang
Publikationsdatum
02.12.2019
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 2/2020
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-019-10011-4

Neu im Fachgebiet Onkologie

Neue chemotherapiefreie Kombinationstherapie punktet bei CLL

Zwischenergebnisse der Phase-III-Studie AMPLIFY sprechen dafür, dass die zeitlich begrenzte Behandlung mit Acalabrutinib und Venetoclax fitte Personen mit chronischer lymphatischer Leukämie länger leben lässt als eine Chemoimmuntherapie.

NRG1-Fusionen als neues, klinisch relevantes Target

Ergebnisse einer Phase-II-Studie deuten darauf hin, dass ein gegen HER3 und HER2 gerichteter Antikörper bei verschiedenen NRG1-Fusions-positiven Tumoren wirksam sein könnte. In den USA ist die Substanz bereits beschleunigt zugelassen worden.

Die aktuelle S3-Leitlinie zu CLL strotzt vor Neuerungen

Vor kurzem wurde eine neue, grundlegend überarbeite Version der S3-Leitlinie Chronische Lymphatische Leukämie (CLL) veröffentlicht.  Zu den wichtigsten Änderungen gehört, dass die Chemoimmuntherapie auf dem Rückzug ist.

Gluteuslappen nach Rektumkarzinom-Op. schützt vor Abszessen

Die Wunddeckung mit einem autologen Rotationslappen nach Entfernung eines Rektumkarzinoms konnte in einer randomisierten Studie gegenüber dem primären Wundverschluss vor allem in einer Hinsicht punkten: Sie führte deutlich seltener zu präsakralen Abszessen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.